Xcovery Acquires Majority Controlling Stake in Meryx Pharmaceuticals

Chimerix Acquires Oncoceutics

January 7, 2021

Biotechnology

Chimerix (NASDAQ: CMRX) acquired clinical-stage Oncoceutics, gaining the late-stage oncology candidate ONC201 to expand its oncology pipeline. The deal closed January 7, 2021, for $78 million (half stock, half cash) plus potential milestones and royalties.

Astellas Pharma Acquires Xyphos Biosciences

December 26, 2019

Biotechnology

Astellas Pharma has acquired Xyphos Biosciences, gaining Xyphos' ACCEL convertible-CAR technology platform and immuno-oncology talent. The deal included $120 million paid at closing and potential milestone payments bringing the total transaction value to up to $665 million.

Medicure Inc. Acquires Marley Drug, Inc.

December 15, 2020

Healthcare Services

Medicure Inc., through its wholly-owned U.S. subsidiary Medicure Pharma Inc., agreed to acquire 100% of Marley Drug, Inc., a specialty mail-order pharmacy based in North Carolina, for an upfront USD $6.3 million plus contingent payments. Marley serves over 30,000 customers nationwide, generated approximately $7.0 million of revenue and more than $1.7 million of EBITDA for the 12 months ended October 31, 2020, and the acquisition expands Medicure's direct-to-patient distribution and specialty pharmacy capabilities in the United States.

Gilead Sciences Acquires XinThera

May 9, 2023

Biotechnology

Gilead Sciences has acquired all outstanding shares of XinThera, a San Diego–based private biotechnology company, adding small-molecule oncology and inflammation programs (including PARP1-selective and MK2-targeting assets) to its early pipeline. Financial terms were not disclosed; XinThera was backed by investors including Foresite Capital, OrbiMed and TTM Capital.

Merck Acquires Caraway Therapeutics

November 21, 2023

Biotechnology

Merck (MSD) will acquire Caraway Therapeutics, a Cambridge, Massachusetts–based preclinical biopharmaceutical company, for up to $610 million in potential consideration, including an undisclosed upfront payment and contingent milestone payments. The acquisition is intended to strengthen Merck’s research pipeline and capabilities in developing small-molecule treatments for genetically defined neurodegenerative and rare diseases.

Turnstone Biologics Acquires Myst Therapeutics

January 20, 2021

Biotechnology

Turnstone Biologics Corp., a privately held clinical-stage biotechnology company, has acquired California-based Myst Therapeutics to integrate Myst’s tumor-infiltrating lymphocyte (TIL) selection and expansion platform into Turnstone’s oncolytic virus and cell therapy pipeline. The acquisition grants Turnstone full access to Myst’s R&D capabilities, development collaborations, and a TIL program with a lead candidate expected to enter the clinic soon; financial terms were not disclosed.